All Articles

Zacks Investment Management launches two new income ETFs, ZINC and PRIZ, targeting an 8% yield. But can their 'simple', research-driven approach deliver?

Frazier Healthcare Partners adds Milton Boyer as an EIR, signaling a strategic push into the complex pharmaceutical manufacturing sector with a proven operator.

As AI-powered cyberattacks escalate, one company is fighting fire with fire. Skyhawk Security's award-winning AI Red Team is a game-changer.

AI is moving from the cloud to the world around us. New, powerful hardware is making our cities and industries smarter, but it demands a new level of trust.

Co-Diagnostics is developing a point-of-care Ebola test promising 30-minute results. But can it navigate regulatory hurdles and reach the front lines in time?

Medscape's new AI symposium aims to guide hematologists through an ethical revolution, promising to enhance, not replace, clinical expertise. Is this the future?

As a key architect of its global manufacturing retires, Alliance Laundry bets on financial discipline and investor savvy to drive its next growth cycle.

With a $1.25 billion investment from Apollo Funds, McKesson is spinning off its medical supply unit. Is this a cure for corporate bloat or a new symptom of financialization in healthcare?

The 'better-for-you' brand is betting on a booming peanut butter market with its first non-chocolate snack, a strategic move backed by deep market data.

After a turbulent past, Movement is betting its future on a new model for emerging markets, marrying licensed payment rails with blockchain. Is it a true revolution?

TELUS's #StandWithOwners returns, but its new focus on a year-round community reveals a deeper strategy: building an ecosystem, not just running a contest.

A new study on couples' supplements shows impressive well-being gains, but a closer look at the methodology reveals a gap between marketing and hard science.

As AI and cyber risks escalate, the new 'Chief Trust Officer' role is emerging. HITRUST's appointment of a veteran leader signals a major shift for all.

With an $18M Series A, Novellia is flipping the script on real-world data, empowering patients to solve a decades-old, multi-billion-dollar R&D bottleneck.

Upcoming study results for Bayer's KERENDIA could unlock a new treatment for millions with non-diabetic chronic kidney disease, a vast and underserved group.

With the appointment of Roku and Viant veteran Tom Wolfe, Locality signals a major play to solve local TV's biggest challenges: fragmentation and opacity.

While others chase fleeting trends, one Colorado agency built a decade of success on a radical idea: sustainability over scale. Here's the analysis.

With real estate worth more than its stock and ambitious R&D plans, Cosmos Health claims it's undervalued. But is an unusual crypto strategy clouding the picture?

A new partnership between SoundExchange and IFPI automates a critical piece of music's data puzzle, promising fairer pay and less bureaucracy for indie artists.

The Dallas Cowboys are using a new device to build muscle. It’s part of a high-stakes trend where technology is redefining athlete recovery and longevity.